Barinthus Biotherapeutics Statistics
Total Valuation
BRNS has a market cap or net worth of $40.14 million. The enterprise value is -$47.06 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BRNS has 40.34 million shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 40.34M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 11.88% |
| Owned by Institutions (%) | 24.52% |
| Float | 26.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.64 |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.18, with a Debt / Equity ratio of 0.10.
| Current Ratio | 9.18 |
| Quick Ratio | 8.60 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -920.93 |
Financial Efficiency
Return on equity (ROE) is -45.42% and return on invested capital (ROIC) is -19.90%.
| Return on Equity (ROE) | -45.42% |
| Return on Assets (ROA) | -18.20% |
| Return on Invested Capital (ROIC) | -19.90% |
| Return on Capital Employed (ROCE) | -38.25% |
| Revenue Per Employee | $142,562 |
| Profits Per Employee | -$621,267 |
| Employee Count | 105 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.62% in the last 52 weeks. The beta is -0.77, so BRNS's price volatility has been lower than the market average.
| Beta (5Y) | -0.77 |
| 52-Week Price Change | -49.62% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 54.11 |
| Average Volume (20 Days) | 49,684 |
Short Selling Information
| Short Interest | 35,731 |
| Short Previous Month | 52,440 |
| Short % of Shares Out | 0.14% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.06 |
Income Statement
In the last 12 months, BRNS had revenue of $14.97 million and -$65.23 million in losses. Loss per share was -$1.64.
| Revenue | 14.97M |
| Gross Profit | 16.07M |
| Operating Income | -49.73M |
| Pretax Income | -65.25M |
| Net Income | -65.23M |
| EBITDA | -46.53M |
| EBIT | -49.73M |
| Loss Per Share | -$1.64 |
Full Income StatementBalance Sheet
The company has $99.12 million in cash and $11.92 million in debt, giving a net cash position of $87.20 million or $2.16 per share.
| Cash & Cash Equivalents | 99.12M |
| Total Debt | 11.92M |
| Net Cash | 87.20M |
| Net Cash Per Share | $2.16 |
| Equity (Book Value) | 115.59M |
| Book Value Per Share | 2.86 |
| Working Capital | 97.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.02 million and capital expenditures -$589,000, giving a free cash flow of -$32.61 million.
| Operating Cash Flow | -32.02M |
| Capital Expenditures | -589,000 |
| Free Cash Flow | -32.61M |
| FCF Per Share | -$0.81 |
Full Cash Flow StatementMargins
| Gross Margin | 107.35% |
| Operating Margin | -332.22% |
| Pretax Margin | -436.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | -162.52% |
| FCF Yield | -81.24% |
Analyst Forecast
The average price target for BRNS is $3.00, which is 203.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 203.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BRNS has an Altman Z-Score of -1.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.46 |
| Piotroski F-Score | 3 |